Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Bioluminescence imaging has previously been used to monitor the formation of grafted tumors in vivo and measure cell number during tumor progression and response to therapy. The development and optimization of successful cancer therapy strategies may well require detailed and specific assessment of biological processes in response to mechanistic intervention. Here, we use bioluminescence imaging to monitor the cell cycle in a genetically engineered, histologically accurate model of glioma in vivo. In these platelet-derived growth factor (PDGF)-driven oligodendrogliomas, G1 cell-cycle arrest is generated by blockade of either the PDGF receptor or mTOR using small-molecule inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PDGF/ERK signalling activates cell cycle regulators to stimulate proliferation24,25, and βPDGFRαTg islets had elevated levels of Ccnd1 mRNA encoding cyclin D1, and increased β-cells with nuclear cyclin D1 and phosphorylated Rb protein (Fig. 5c–e and Supplementary Fig. 9a).”
From PDGF signalling controls age-dependent proliferation in pancreatic β-cells (2011) · cites this paper as [24]
Citations
Cites
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
Massoud, T. F., & Gambhir, S. S. (2003) · Genes & Development · doi:10.1101/gad.1047403 · Cited by 2,216
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
Dai, C., Celestino, J. C., Okada, Y., Louis, D. N., Fuller, G. N., & Holland, E. C. (2001) · Genes & Development · doi:10.1101/gad.903001 · Cited by 708
Self-citationAn inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Visualizing Gene Expression in Living Mammals Using a Bioluminescent Reporter
Contag, C. H., Spilman, S. D., Contag, P. R., Oshiro, M., Eames, B., Dennery, P., Stevenson, D. K., & Benaron, D. A. (1997) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1997.tb03184.x · Cited by 526
Bioluminescent indicators in living mammals
Contag, P. R., Olomu, I. N., Stevenson, D. K., & Contag, C. H. (1998) · Nature Medicine · doi:10.1038/nm0298-245 · Cited by 517
Johnson, D. G., Ohtani, K., & Nevins, J. R. (1994) · Genes & Development · doi:10.1101/gad.8.13.1514 · Cited by 494
Gliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 461
Self-citationRapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging
Rehemtulla, A., Stegman, L. D., Cardozo, S. J., Gupta, S., Hall, D. E., Contag, C. H., & Ross, B. D. (2000) · Neoplasia · doi:10.1038/sj.neo.7900121 · Cited by 460
Research works printed but not linked: 1
- Shih, A. et al. Dose dependent effects of PDGF-B on glial tumorigenesis. Cancer Res. (in press).
Cited by
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Self-citationMaximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Illuminating the metastatic process
Sahai, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2229 · Cited by 569
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C. I., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 521
Self-citationMonitoring Tumorigenesis and Senescence In Vivo with a p16INK4a-Luciferase Model
Burd, C. E., Sorrentino, J. A., Clark, K. S., Darr, D. B., Krishnamurthy, J., Deal, A. M., Bardeesy, N., Castrillon, D. H., Beach, D. H., & Sharpless, N. E. (2013) · Cell · doi:10.1016/j.cell.2012.12.010 · Cited by 419
“In contrast, several “tumor-specific” reporter alleles have been reported in the literature (e.g., E2f-LUC [Uhrbom et al., 2004], ARF-GFP [Zindy et al., 2003], ODD-Luc [Goldman et al., 2011; Safran et al., 2006], and p21-p-luc [Ohtani et al., 2007]), but these models are not ideal as they are…”
Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma
Ozawa, T., Riester, M., Cheng, Y.-K., Huse, J. T., Squatrito, M., Helmy, K., Charles, N., Michor, F., & Holland, E. C. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.005 · Cited by 386
“The RCAS/tv-a system used in this work has been described previously (Holland et al., 1998, 2000; Holland and Varmus, 1998; Hu et al., 2005; Uhrbom et al., 2004).”
MethodSelf-citationCorticosteroids compromise survival in glioblastoma
Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S., Dai, C., Ozawa, T., Chang, M., Chan, T. A., et al. (2016) · Brain · doi:10.1093/brain/aww046 · Cited by 363
“We have previously described a Ntva;Ef-Luc transgenic mouse that expresses firefly luciferase driven by the E2f1 promoter (Ef-Luc) (Uhrbom et al., 2004).”
BackgroundMethodSelf-citationCellular imaging in drug discovery
Lang, P., Yeow, K., Nichols, A., & Scheer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2008 · Cited by 351
“In one example, a transgenic mouse expressing a fusion protein between luciferase and the transcription factor E2F”
BackgroundPDGF signalling controls age-dependent proliferation in pancreatic β-cells
Chen, H., Gu, X., Liu, Y., Wang, J., Wirt, S. E., Bottino, R., Schorle, H., Sage, J., & Kim, S. K. (2011) · Nature · doi:10.1038/nature10502 · Cited by 278
Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
Leder, K., Pitter, K., LaPlant, Q., Hambardzumyan, D., Ross, B. D., Chan, T. A., Holland, E. C., & Michor, F. (2014) · Cell · doi:10.1016/j.cell.2013.12.029 · Cited by 267
“We generated PDGF-B-induced tumors in Nestintv-a;E2f1-Luc mice using the replication-competent ASLV long-terminal repeat (LTR) with a splice acceptor (RCAS)/t-va mouse-model system (Uhrbom et al., 2004).”
MethodSelf-citationThe Pathobiology of Glioma Tumors
Gladson, C. L., Prayson, R. A., & Liu, W. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102109 · Cited by 254
“Frequently, expression of both the ligand and the receptor is increased in glioma tumors, suggesting that there exists an autocrine or paracrine loop that amplifies signaling (65,66).”
BackgroundGross, S., & Piwnica-Worms, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.12.011 · Cited by 229
Yan, D., Kowal, J., Akkari, L., Schuhmacher, A. J., Huse, J. T., West, B. L., & Joyce, J. A. (2017) · Oncogene · doi:10.1038/onc.2017.261 · Cited by 236
Mouse Models of Brain Tumors and Their Applications in Preclinical Trials
Fomchenko, E. I., & Holland, E. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0438 · Cited by 226
Self-citationMouse models of glioblastoma for the evaluation of novel therapeutic strategies
Haddad, A. F., Young, J. S., Amara, D., Berger, M. S., Raleigh, D. R., Aghi, M. K., & Butowski, N. A. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab100 · Cited by 203
The perivascular niche microenvironment in brain tumor progression
Charles, N. A., & Holland, E. C. (2010) · Cell Cycle · doi:10.4161/cc.9.15.12710 · Cited by 199
Self-citationBioluminescent imaging: a critical tool in pre‐clinical oncology research
O'Neill, K., Lyons, S. K., Gallagher, W. M., Curran, K. M., & Byrne, A. T. (2010) · The Journal of Pathology · doi:10.1002/path.2656 · Cited by 174
“factor) receptor activation, both critical for glioma maintenance [40].”
BackgroundMethodInfluentialMomota, H., Nerio, E., & Holland, E. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1042 · Cited by 177
“We previously showed thatmTOR blockade results in inhibition of proliferation in PDGF-induced mouse gliomas (18).”
BackgroundSelf-citationJacobs, A. H., Kracht, L. W., Gossmann, A., Rüger, M. A., Thomas, A. V., Thiel, A., & Herholz, K. (2005) · NeuroRX · doi:10.1602/neurorx.2.2.333 · Cited by 173
De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA
Wiesner, S. M., Decker, S. A., Larson, J. D., Ericson, K., Forster, C., Gallardo, J. L., Long, C., Demorest, Z. L., Zamora, E. A., Low, W. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1800 · Cited by 171
“In the RCAS model, FLuc was expressed only in dividing cells (14) or when the Gli pathway is activated (39).”
MethodDecaestecker, C., Debeir, O., Van Ham, P., & Kiss, R. (2007) · Medicinal Research Reviews · doi:10.1002/med.20078 · Cited by 165
“In combination with animal models of cancer that use the stable expression of green fluorescent protein (GFP) from tissue-specific promoters, this enables cell behavior in primary tumors in live animals to be observed directly.(45,151,152) Alternatively, optical sectioning techniques are able to produce high-resolutio…”
BackgroundNG2 Cells in White Matter But Not Gray Matter Proliferate in Response to PDGF
Hill, R. A., Patel, K. D., Medved, J., Reiss, A. M., & Nishiyama, A. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2001-12.2013 · Cited by 166
“Furthermore, inhibiting mTOR with a rapamycin analog has been shown to inhibit proliferation of PDGF-induced gliomas in mice (Uhrbom et al., 2004).”
BackgroundNon-Invasive Detection of a Small Number of Bioluminescent Cancer Cells In Vivo
Kim, J.-B., Urban, K., Cochran, E., Lee, S., Ang, A., Rice, B., Bata, A., Campbell, K., Coffee, R., Gorodinsky, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009364 · Cited by 156
“efficacy[21,22,23].”
Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing
Huse, J. T., & Holland, E. C. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00234.x · Cited by 158
“This strategy, in the context of a PDGF-driven glioma GEMM, has been used to successfully monitor the effects of pharmacologic PDGFR inhibition on tumor growth (80).”
BackgroundMethodSelf-citationSarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061537 · Cited by 150
Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D. A., Babić, I., Villa, G. R., Tanaka, K., Nael, A., Yang, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0502 · Cited by 159
“In mouse genetic models, PDGF-B ligand overexpression can promote gliomagenesis by enhancing cellular proliferation (30-34).”
Biomarker system for studying muscle, stem cells, and cancer in vivo
Nishijo, K., Hosoyama, T., Bjornson, C. R. R., Schaffer, B. S., Prajapati, S. I., Bahadur, A. N., Hansen, M. S., Blandford, M. C., McCleish, A. T., Rubin, B. P., et al. (2009) · The FASEB Journal · doi:10.1096/fj.08-128116 · Cited by 133
“55 10(10) photons/cm(2)/s/ sr, which is comparable to or greater than previously reported, useful monocistronic luciferase reporters (2, 3, 23).”
BackgroundGenetic modeling of gliomas in mice: New tools to tackle old problems
Hambardzumyan, D., Parada, L. F., Holland, E. C., & Charest, A. (2011) · Glia · doi:10.1002/glia.21142 · Cited by 98
“The mTOR inhibitor CCI779 and the PDGF/VEGF inhibitor PTK787 were shown to achieve similar growth arrests against this tumor type (Uhrbom et al., 2004).”
BackgroundSelf-citationXing, D., & Orsulic, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502256102 · Cited by 100
Glioblastoma: Molecular Analysis and Clinical Implications
Huse, J. T., Holland, E., & DeAngelis, L. M. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-100711-143028 · Cited by 97
Self-citationTumor-specific imaging through progression elevated gene-3 promoter-driven gene expression
Bhang, H.-E. C., Gabrielson, K. L., Laterra, J., Fisher, P. B., & Pomper, M. G. (2010) · Nature Medicine · doi:10.1038/nm.2269 · Cited by 88
Molecular imaging strategies for drug discovery and development
Gross, S., & Piwnica-Worms, D. R. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.028 · Cited by 95
Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma
Trejo‐Solís, C., Serrano‐García, N., Escamilla-Ramírez, Á., Castillo‐Rodríguez, R. A., Jiménez‐Farfán, D., Palencia, G., Calvillo, M., Lemus, M. A. A., Flores‐Nájera, A., Cruz-Salgado, A., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123773 · Cited by 92
“Temsirolimus has antiproliferative effects in mouse low-grade gliomas [270].”
BackgroundLuo, J., Lin, A. H., Masliah, E., & Wyss-Coray, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605077103 · Cited by 77
McConville, P., Hambardzumyan, D., Moody, J. B., Leopold, W. R., Kreger, A. R., Woolliscroft, M. J., Rehemtulla, A., Ross, B. D., & Holland, E. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3058 · Cited by 84
Self-citationFomchenko, E. I., Dougherty, J. D., Helmy, K. Y., Katz, A. M., Pietras, A., Brennan, C., Huse, J. T., Milosevic, A., & Holland, E. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020605 · Cited by 77
“gliomas retain their dependence on PDGFR signaling [39].”
BackgroundSelf-citationOhtani, N., Imamura, Y., Yamakoshi, K., Hirota, F., Nakayama, R., Kubo, Y., Ishimaru, N., Takahashi, A., Hirao, A., Shimizu, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706949104 · Cited by 73
Noninvasive Molecular Imaging Using Reporter Genes
Brader, P., Serganova, I. S., & Blasberg, R. G. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.099788 · Cited by 79
“Other examples of imaging oncogenesis include platelet-derived growth factor (PDGF)–induced gliomas (47), the PSA-luc prostate cancer model (48), and the pVEGF-TSTA-luc reporter for a mammary tumorigenesis model (49).”
BackgroundMethodInsights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches
Tripathy, D. K., Panda, L. P., Biswal, S., & Barhwal, K. K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1355242 · Cited by 84
“Inhibiting PDGF signaling improves the sensitivity of anti-VEGF/VEGFR therapy in GB, allowing for the creation of more effective treatment regimens (Uhrbom et al., 2004).”
BackgroundHervouet, É., Debien, E., Campion, L., Charbord, J., Ménanteau, J., Vallette, F. M., & Cartron, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2062 · Cited by 81
Myburgh, E., Coles, J. A., Ritchie, R., Kennedy, P. G. E., McLatchie, A. P., Rodgers, J., Taylor, M. C., Barrett, M. P., Brewer, J. M., & Mottram, J. C. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002384 · Cited by 68
“[43,46,47].”
Pitter, K. L., Galbán, C. J., Galbán, S., Tehrani, O. S., Li, F., Charles, N. A., Bradbury, M. S., Becher, O. J., Chenevert, T. L., Rehemtulla, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014545 · Cited by 73
“Data from our laboratory using CCI-779 in a mouse model of PDGF-B driven low-grade gliomas demonstrated dramatic anti-proliferative effect in these tumors [13].”
MethodSelf-citationKocher, B. A., & Piwnica-Worms, D. R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0503 · Cited by 69
High-grade glioma mouse models and their applicability for preclinical testing
de Vries, N. A., Beijnen, J. H., & van Tellingen, O. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.011 · Cited by 77
Dai, C., Lyustikman, Y., Shih, A. H., Hu, X., Fuller, G. N., Rosenblum, M. K., & Holland, E. C. (2005) · Neoplasia · doi:10.1593/neo.04691 · Cited by 63
“is low in these tumors, it is required for their proliferation [35].”
BackgroundSelf-citationDeroose, C. M., Reumers, V., Gijsbers, R., Bormans, G. M., Debyser, Z., Mortelmans, L. A., & Baekelandt, V. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.007 · Cited by 70
“00 been used to track ex vivo-transduced and implanted neuronal progenitor cells [4,5], to monitor the growth of implanted [6–8] and spontaneous [9,10] brain tumors, to determine gene expression after adenoviral vector injection in orthotopic brain tumors [11], and to monitor treatment of herpes simplex encephalitis […”
MethodPlatelet-derived growth factor in glioblastoma—driver or biomarker?
Westermark, B. (2014) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2014.970304 · Cited by 72
“These results are in striking contrast to studies on PDGFB-induced gliomas inmice, where lowmolecular-weight PDGF receptor kinase inhibitors are efficacious in reverting the transformed phenotype and cause tumor growth retardation in vivo (67).”
ResultMeasuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
Jost, S. C., Collins, L. I., Travers, S. S., Piwnica-Worms, D. R., & Garbow, J. R. (2009) · Molecular Imaging · doi:10.2310/7290.2009.00023 · Cited by 68
Ohtani, N., Yamakoshi, K., Takahashi, A., & Hara, E. (2010) · Cell Division · doi:10.1186/1747-1028-5-1 · Cited by 62
“Optical imaging by bioluminescence allows a non-invasive and real-time analysis of various biological responses in living animals, such as gene expression, proteolytic processing or protein-protein interactions in living animals [31-36].”
Jiang, Y., Boije, M., Westermark, B., & Uhrbom, L. (2011) · Neoplasia · doi:10.1593/neo.11314 · Cited by 58
“Our results are in line with earlier data, which showed that when PDGF-B–induced tumor-bearing mice were treated with the PDGF-receptor inhibitor PTK787, the tumor cells stopped proliferating, but there was no sign of apoptosis [21].”
ResultSelf-citationNoninvasive Bioluminescence Imaging of Normal and Spontaneously Transformed Prostate Tissue in Mice
Lyons, S. K., Lim, E., Clermont, A. O., Dusich, J., Zhu, L., Campbell, K. D., Coffee, R. J., Grass, D., Hunter, J., Purchio, T. F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3598 · Cited by 56
“actions (12–14), proteasome activity (15), apoptosis (16), and tumor cell proliferation (17) noninvasively in living mice.”
BackgroundGlioblastoma and malignant astrocytoma
Sarkar, A., & Chiocca, E. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06967-3.00021-1 · Cited by 56
Molecular Imaging: Reporter Gene Imaging
Serganova, I. S., Mayer-Kuckuk, P., Huang, R., & Blasberg, R. G. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-77496-9_8 · Cited by 52
Tumor Progression and Oncogene Addiction in a PDGF-B-Induced Model of Gliomagenesis
Calzolari, F., Appolloni, I., Tutucci, E., Caviglia, S., Terrile, M., Corte, G., & Malatesta, P. (2008) · Neoplasia · doi:10.1593/neo.08814 · Cited by 54
“Although other authors already showed that the development of PDGF-B induced tumors is dependent on continuous PDGF-B signaling [30,31], our data represent the first demonstration that fully progressed tumors remain addicted to their triggering oncogenic stimulus.”
BackgroundNovel approaches to glioma drug design and drug screening
Patil, S. A., Hosni-Ahmed, A., Jones, T. S., Patil, R., Pfeffer, L. M., & Miller, D. D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.807248 · Cited by 46
“It is based on bioluminescence reaction in which the luciferase enzyme oxidizes its substrate luciferin and emits photons that can be measured by Xenogen in vivo animal imaging system [92-94].”
MethodTang, W., Xing, Z., Hu, W., Li, C., Wang, J., & Wang, Y. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7581-x · Cited by 46
Brutkiewicz, S. A., Mendonca, M. S., Stantz, K. M., Comerford, K., Bigsby, R. M., Hutchins, G. D., Goebl, M. G., & Harrington, M. A. (2007) · Luminescence · doi:10.1002/bio.953 · Cited by 50
A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line
Bryant, M., Chuah, T., Luff, J., Lavin, M. F., & Walker, D. (2008) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2007.04.022 · Cited by 44
Applications of mouse glioma models in preclinical trials
Hu, X., & Holland, E. C. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.023 · Cited by 44
Self-citationMolecular Imaging of Brain Tumors: A Bridge Between Clinical and Molecular Medicine?
Schaller, B. J., Modo, M., & Buchfelder, M. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-006-0069-9 · Cited by 39
Imaging Mouse Cancer Models In Vivo Using Reporter Transgenes
Lyons, S. K., Patrick, P. S., & Brindle, K. M. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069864 · Cited by 45
“For example, a reporter transgene driven by the S-phase-speci fi c E2F promoter was used to show that the mechanism of a drug was cytostatic rather than cytotoxic in a mouse model of glioma (Uhrbom et al. 2004).”
Bradbury, M. S., Hambardzumyan, D., ZANZONICO, P. B., Schwartz, J., Cai, S., Burnazi, E. M., Longo, V. A., Larson, S. M., & Holland, E. C. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047092 · Cited by 37
“Within 24 h of birth, Ntv-a/Ink4a2/2Arf2/2 mice were injected intracranially with 104 DF-1 cells infected with and producing RCAS-PDGF retroviral vectors as previously described (23).”
MethodSelf-citationGross, S., Abraham, U., Prior, J. L., Herzog, E. D., & Piwnica-Worms, D. R. (2007) · Molecular Imaging · doi:10.2310/7290.2007.00009 · Cited by 37
Imaging Bone Morphogenetic Protein 7 Induced Cell Cycle Arrest in Experimental Gliomas
Klose, A., Waerzeggers, Y., Monfared, P., Vukičević, S., Kaijzel, E. L., Winkeler, A., Wickenhauser, C., Löwik, C. W. G. M., & Jacobs, A. H. (2011) · Neoplasia · doi:10.1593/neo.101540 · Cited by 35
“Bioluminescence imaging represents a useful and highly sensitive technique to study glioma cell proliferation and effects of antiproliferative compounds [36,37].”
BackgroundSato, K., Yuasa, T., Nogawa, M., Kimura, S. H., Segawa, H., Yokota, A., & Maekawa, T. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603423 · Cited by 32
“1356 British Journal of Cancer (2006) 95(10), 1354 – 1361 & 2006 Cancer Research UK T ra n sla tio n a l T h e ra p e u tic s viscera by measuring these photon signals (Adams et al, 2002; Hollingshead et al, 2004; Uhrbom et al, 2004; Nogawa et al, 2005a, c).”
BackgroundBioluminescence technology for imaging cell proliferation
Momota, H., & Holland, E. C. (2005) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2005.10.012 · Cited by 29
Self-citationMolecular Imaging of Experimental Abdominal Aortic Aneurysms
Ramaswamy, A. K., Hamilton, M., Joshi, R. V., Kline, B. P., Li, R., Wang, P., & Goergen, C. J. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/973150 · Cited by 28
PDGF in gliomas: more than just a growth factor?
Lindberg, N., & Holland, E. C. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.654860 · Cited by 29
“One study has demonstrated how PTK787-mediated inhibition of PDGF signaling in PDGF-B-induced gliomas results in a markedly reduced proliferation without elimination of tumors, indicating that these tumors are dependent on PDGF signaling to maintain proliferative capacity while inhibition does not eliminate tumors (64…”
Self-citationConnolly, N. P., Shetty, A. C., Stokum, J. A., Hoeschele, I., Siegel, M. B., Miller, C. R., Kim, A. J., Ho, C., Dávila, E., Simard, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19451-6 · Cited by 28
Self-citationA review of gliomas-related proteins. Characteristics of potential biomarkers.
Pienkowski, T., Kowalczyk, T., Kretowski, A. J., & Ciborowski, M. (2021) · PubMed · Cited by 31
Genetically engineered mouse models of diffuse gliomas
Schmid, R. S., Vitucci, M., & Miller, C. R. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.06.002 · Cited by 28
“rugs like TMZ [60] or novel targeted agents [97,114].”
DNA Nanoparticles: Detection of Long-Term Transgene Activity in Brain using Bioluminescence Imaging
Yurek, D. M., Fletcher, A. M., McShane, M., Kowalczyk, T. H., Padegimas, L., Weatherspoon, M. R., Kaytor, M. D., Cooper, M. J., & Ziady, A. G. (2011) · Molecular Imaging · doi:10.2310/7290.2010.00053 · Cited by 24
Transgenic Animal Models to Visualize Cancer-Related Cellular Processes by Bioluminescence Imaging
Manni, I., de Latouliere, L., Gurtner, A., & Piaggio, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00235 · Cited by 24
Connolly, N. P., Stokum, J. A., Schneider, C. S., Ozawa, T., Xu, S., Galisteo, R., Castellani, R. J., Kim, A. J., Simard, J. M., Winkles, J. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174557 · Cited by 23
Self-citationMüller, J. M., Wunder, A., & Licha, K. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-10853-2_7 · Cited by 22
Zhang, G., Chen, T., Bednár̂, B., Connolly, B., Hargreaves, R. J., Sur, C., & Williams, D. L. (2007) · Neoplasia · doi:10.1593/neo.07421 · Cited by 21
“p53, E2F, or hypoxia-inducible factors) [1–4], it becomes possible to monitor a particular pathway or process regulated by a transcriptional factor.”
BackgroundPericytes orchestrate a tumor-restraining microenvironment in glioblastoma
Braun, S., Bolívar, P., Oudenaarden, C., Sjölund, J., Bocci, M., Harbst, K., Talkhoncheh, M. S., Phung, B., Cordero, E., Rosberg, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66985-1 · Cited by 24
“The RCAS/tv-a system used in this study has been described previously 116 – 119 .”
Using bioluminescence imaging in glioma research
Luwor, R. B., Stylli, S. S., & Kaye, A. H. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.11.001 · Cited by 19
“vention [12,85–87].”
BackgroundIdentifying candidate genes involved in brain tumor formation
Swartling, F. J. (2008) · Upsala Journal of Medical Sciences · doi:10.3109/2000-1967-215 · Cited by 20
Modeling Resistance to Pathway-Targeted Therapy in Ovarian Cancer
Xing, D., & Oršulić, S. (2005) · Cell Cycle · doi:10.4161/cc.4.8.1869 · Cited by 20
Imaging Mouse Models of Cancer
Lyons, S. K. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000112 · Cited by 19
Rodent Models to Analyze the Glioma Microenvironment
Hetze, S., Sure, U., Schedlowski, M., Hadamitzky, M., & Barthel, L. (2021) · ASN NEURO · doi:10.1177/17590914211005074 · Cited by 19
Kanvinde, P. P., Malla, A. P., Connolly, N. P., Szulzewsky, F., Anastasiadis, P., Ames, H. M., Kim, A. J., Winkles, J. A., Holland, E. C., & Woodworth, G. F. (2021) · Glia · doi:10.1002/glia.23984 · Cited by 19
“Furthermore, genetic manipulations such as introducing bioluminescence reporters (Uhrbom et al., 2004, Becher et al., 2008; Ene et al., 2020), fluorescence reporters (Becher et al., 2010; Lindberg et al., 2009; Alexander et al., 2020; Halliday et al., 2014), and cell barcodes (Sanz et al., 2009)…”
BackgroundInfluentialSelf-citationOptical molecular imaging in drug discovery and clinical development
Bednár̂, B., Zhang, G., Williams, D. L., Jr., Hargreaves, R. J., & Sur, C. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.65 · Cited by 19
Animal models for glioma drug discovery
Jones, T. S., & Holland, E. C. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.632628 · Cited by 16
“The use of imaging modalities such as MRI and BLI provides the opportunity to confirm the tumor presence and monitor the tumor’s response to therapy in vivo over time without 1278 Expert Opin.”
BackgroundInfluentialSelf-citationMajumdar, K., Radotra, B. D., Vasishta, R. K., & Pathak, A. (2009) · Surgical Neurology · doi:10.1016/j.surneu.2008.10.001 · Cited by 16
“Uhrbom et al [28] used bioluminescence imaging to monitor the cell cycle in a genetically engineered mouse glioma model and found that in PDGF-driven oligodendrogliomas, G1 cell cycle arrest is generated by blockade of PDGF receptor.”
MethodYang, X., Feng, P., Ma, L., Kang, T., Hu, S., Hai, A., Ke, B., Liu, J., & Li, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112476 · Cited by 16
Prins, R. M., Bruhn, K. W., Craft, N. A., Lin, J. W., Kim, C. H., Odesa, S. K., Miller, J. F., & Liau, L. M. (2005) · Neurosurgery · doi:10.1227/01.neu.0000192367.29047.64 · Cited by 16
“BLI can also detect changes in CNS tumor progression induced by chemotherapy (37, 44) or intratumoral injections of chimeric T cells in nude mice (20).”
BackgroundIglesias, P., Seoane, M., Golán, I., Castro‐Piedras, I., Fraga, M., Arce, V. M., & Costoya, J. A. (2020) · Cancers · doi:10.3390/cancers12102907 · Cited by 15
“To complement this data, Parp1+/+ Rb+/+, Parp1−/−, Parp1+/+ Rb−/−, Parp1−/− Rb−/−, and Parp1+/+ fibroblasts were transfected with a reporter construct driven by a minimal promoter with upstream E2F binding sites (pE2F-Luc) [23].”
MethodYamaguchi, S., Iikubo, E., Hirose, N., Kitajima, T., Katagiri, S., Kawamori, A., Fujii-Taira, I., Matsushima, T., & Homma, K. J. (2010) · Neuroscience Research · doi:10.1016/j.neures.2010.02.007 · Cited by 15
Munley, M. T., Kagadis, G. C., McGee, K. P., Kirov, A. S., Jang, S., Mutic, S., Jeraj, R., Xing, L., & Bourland, J. D. (2013) · Medical Physics · doi:10.1118/1.4819818 · Cited by 15
Stell, A., Biserni, A., Torre, S. D., Rando, G., Ramachandran, B., Ottobrini, L., Lucignani, G., Maggi, A. C., & Ciana, P. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.019 · Cited by 14
“P53*, E2F/Rb, AP-1, NFkB Transcriptional activity No*/yes Carlsen et al. (2002), Doubrovin et al. (2001), Huang et al. (1997), and Uhrbom et al. (2004) *Reporter mice for p53 transcriptional activity have never been generated.”
BackgroundNoninvasive Assessment of E2F-1–Mediated Transcriptional Regulation In vivo
Monfared, P., Winkeler, A., Klein, M., Li, H., Klose, A., Hösel, M., Waerzeggers, Y., Korsching, S. I., & Jacobs, A. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6373 · Cited by 14
“These results are in accordance with reports demonstrating that E2F-responsive promoters are active in glioma cells because of an excess of free E2F as a result of loss of Rb/E2F repressor complexes (9, 43, 44).”
ResultBioluminescent Approaches for Measuring Tumor Growth in a Mouse Model of Neurofibromatosis
Hawes, J. J., & Reilly, K. M. (2010) · Toxicologic Pathology · doi:10.1177/0192623309357075 · Cited by 13
“The Ef-luc plasmid (ELUX transgene) containing the luciferase gene behind the E2F promotor was a generous gift from Dr. Eric Holland and has been previously described (Uhrbom, Nerio, and Holland 2004).”
Habimana-Griffin, L., Ye, D., Carpenter, J., Prior, J. L., Sudlow, G. P., Marsala, L. I., Mixdorf, M., Rubin, J. B., Chen, H., & Achilefu, S. (2020) · Journal of Biomedical Optics · doi:10.1117/1.jbo.25.2.026004 · Cited by 13
Nakashiba, T., Ogoh, K., Iwano, S., Sugiyama, T., Mizuno‐Iijima, S., Nakashima, K., Mizuno, S., Sugiyama, F., Yoshiki, A., Miyawaki, A., et al. (2023) · Lab Animal · doi:10.1038/s41684-023-01238-6 · Cited by 13
“First, the biodistributions of AkaLumine-HCl and d-luciferin differ. d-luciferin was previously used to conduct BLI in the brain 13,45 .”
Hawes, J. J., Nerva, J. D., & Reilly, K. M. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108321085 · Cited by 13
“Eric Holland).(16) The hygromycin resistance gene was PCR cloned into pEf-CBGlu upstream of the E2F1 promoter for clonal selection.”
MethodLuminescence-based in vivo monitoring of NF-κB activity through a gene delivery approach
Osorio, F. G., Rosa, J. D. L., & Freije, J. M. P. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-19 · Cited by 13
“Different luciferase and fluorescent proteins-based strategies have been developed for monitoring signaling pathways involved in cancer and aging [5-11].”
BackgroundZhang, G., Chen, T., Hargreaves, R. J., Sur, C., & Williams, D. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.52 · Cited by 10
“, while a luciferase cDNA driven by the responsive elements of E2F1 was used to evaluate E2F1 activity and cell proliferatio”
MethodNovel insights on imaging sex hormone-dependent tumourigenesis in vivo
Ramachandran, B., Stell, A., Maravigna, L., Maggi, A. C., & Ciana, P. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0332 · Cited by 10
Metadata
- Authors
- Uhrbom, L., Nerio, E., & Holland, E. C.
- Affiliations
- Uppsala University (SE)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Holland, Eric C
- Venue
- Nature Medicine
- Published
- 2004-10-24
- Volume
- 10
- Issue
- 11
- Pages
- 1257-1260
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2034345257
- Cited by
- 146
- References
- 18
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 13 · 2012: 7
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › bioluminescence and chemiluminescence research
- Keywords
- glioma, bioluminescence imaging, cell proliferation, cell cycle, G1 cell cycle arrest, platelet-derived growth factor, PDGF receptor, mTOR inhibition, genetically engineered mouse models, tumor maintenance, oligodendroglioma
- MeSH terms
- Animals, Cell Cycle, Disease Models, Animal, DNA-Binding Proteins, Immunohistochemistry, Luciferases, Luminescent Measurements, Mice, Transgenic, Oligodendroglioma, Phthalazines, Platelet-Derived Growth Factor, Promoter Regions, Genetic, Protein Kinases, Pyridines, Transcription Factors, DNA Primers, Cell Cycle Proteins, In Situ Nick-End Labeling, Receptor, Platelet-Derived Growth Factor alpha, E2F Transcription Factors, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.